IMMUNOREGULATION IN VIVO AND IN VITRO BY CYTOKINES

细胞因子的体内和体外免疫调节

• 批准号: 3804727
• 负责人: R PURI
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3804727
• 关键词: antineoplastics; cellular immunity; combination cancer therapy; cytokine; cytotoxic T lymphocyte; immunoregulation; immunotherapy; interferons; interleukin 2; interleukin 6; laboratory mouse; leukocyte activation /transformation; lymphokine activated killer cell; macrophage; neoplasm /cancer immunotherapy; passive immunization; tissue /cell culture

In order to understand the mechanism of antitumor effects, we are investigating the role of cytokines in the regulation of immunity in vitro and in vivo. Interferon-alpha (IFN-alpha), IL-2, IL-6 and other cytokines are investigated. Our initial paper in which we demonstrated that IFN- alpha synergized with IL-2 in the augmentation of lymphokine activated killer (LAK) cells in various compartments of mice is in press. Both proliferation and augmentation of LAK cell activity on a per cell basis was observed in response to IFN-alpha and IL-2 therapy. Our observations suggest that anti-tumor effects of IFN-alpha with IL-2 may be mediated by the activation of LAK cells. It is of interest that the administration of IFN-gamma with IL-2 caused increased LAK activity while it has not been shown to cause synergistic anti-tumor effects. Other effectors such as CTL, macrophages and unknown population may be responsible for the differences observed with the two interferons. Currently, CTL response after IL-2 and IFN-alpha or IFN-gamma administration and augmentation of LAK activity in response to IFN-alpha and gamma alone are being examined. We are also examining the immune regulatory effects of IL-6 in vivo. This project is still active.

为了了解抗肿瘤作用的机制，我们 研究细胞因子在体外免疫调节中的作用 和体内。 干扰素-α (IFN-α)、IL-2、IL-6 和其他细胞因子 被调查。 我们最初的论文中证明了 IFN- α 与 IL-2 协同增强淋巴因子活化 小鼠各个区室中的杀伤细胞（LAK）正在出版。 两个都 每个细胞的 LAK 细胞增殖和活性增强 观察到对 IFN-α 和 IL-2 治疗的反应。 我们的观察 表明 IFN-α 与 IL-2 的抗肿瘤作用可能是通过 LAK 细胞的激活。 令人感兴趣的是，管理 IFN-γ 与 IL-2 引起 LAK 活性增加，但尚未发现 显示出具有协同抗肿瘤作用。 其他效应器如 CTL、巨噬细胞和未知群体可能是造成这种情况的原因 两种干扰素观察到的差异。 目前，CTL回应 IL-2 和 IFN-α 或 IFN-γ 施用并增强后 正在检查 LAK 单独响应 IFN-α 和 γ 的活性。 我们还在研究 IL-6 的体内免疫调节作用。 这 项目仍然活跃。